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Background: Polycystic ovary syndrome (PCOS) is a common and complex endocrine-metabolic disease. One of the
well-documented characteristics of PCOS is obesity or overweightness. It is possible to be genetically predisposed to
becoming obese or overweight, and several potentially causative single nucleotide polymorphisms (SNPs), such as
rs9939609 (A/T) in the fat mass, and obesity-associated gene (FTO) and rs17782313 (T/C) in the melanocortin-4 receptor
gene (MC4R), have been investigated. Further investigation of association between obesity-associated SNPs and PCOS
susceptibility will contribute to a better understanding of the disease.
Methods: In the present study, we enrolled 733 patients with PCOS and 892 control subjects. The common variants
FTO rs9939609 and MC4R rs17782313 were genotyped and their relationship with obesity-related traits was evaluated.
Results: Rs9939609 and rs17782313 are associated with PCOS and obesity-related traits and profiles. The association
found between PCOS and FTO rs9939609 (p = 0.0302) was attenuated after adjustment for BMI (p = 0.187). MC4R
rs17782313 did not confer an increased risk for PCOS (p = 0.368) even after adjustments (p = 0.715). Interestingly, the
interaction of FTO and MC4R polymorphisms was more significantly associated with PCOS (p = 0.031, adjusted for age
and BMI). The FTO variant rs9939609 is associated with Chinese women with PCOS; however, this association is
affected by BMI.
Conclusions: The combined pathogenic effect of FTO and MC4R polymorphisms indicates a direct role of the
interaction between FTO and MC4R polymorphisms in the development of PCOS.
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Polycystic ovary syndrome (PCOS), which affects 6 to
8 % women of reproductive age, is diagnosed by clinical
and/or biochemical androgen excess, menstrual irregu-
larity and polycystic ovaries. Additionally, PCOS patients
are characterized by an increased risk of insulin resist-
ance, type 2 diabetes mellitus, and overweightness/obes-
ity [1–4]. Fifty percent of PCOS patients are overweight
or obese [5], and increasing evidence supports obesity as
being an important factor in the etiology of PCOS [6, 7].
The development of obesity is affected by both genetic
factors and environmental aspects, which is similar to
the development of PCOS [8–10]. It is possible that a
shared genetic predisposition contributes to their co-
occurrence. Scrutinizing obesity-associated genes in* Correspondence: moshen601@126.com
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creativecommons.org/publicdomain/zero/1.0/PCOS patients may help to explain the etiology of both
obesity and PCOS, and identification of susceptibility
genes for either condition has increased with the aim of
eliminating the effects of obesity in PCOS.
The fat mass and obesity-associated gene (FTO), lo-
cated on chromosome 16q12.2, has been identified by
large-scale genome-wide association studies and is rec-
ognized to be associated with both body mass index
(BMI) and obesity [11, 12]. The human FTO gene is
expressed in adipose tissue, muscle, the pancreas, the
liver and adipose tissue, with the highest concentrations
found in the hypothalamus [13]. It has been reported
that the FTO gene is associated with eating habits and is
important in the control of energy homeostasis [14].
rs17782313, located 188 kb downstream of MC4R, was
similarly associated with obesity [15, 16]. Additionally,
the MC4R gene is the most common genetic cause of
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tral melanocortin neuronal pathways [17]. Association
studies have revealed the connection between PCOS and
SNPs in FTO and MC4R, respectively. Regarding FTO,
rs9939609, rs1421085, rs17817449, rs8050136 have been
found to be associated with PCOS, among which
rs9939609 is the most extensively studied and is the only
successfully replicated SNP in Han Chinese populations
[18–25]. In a recent genome-wide association study con-
ducted in Han Chinese women, rs9939609 marginally
achieved genome-wide significance (2.47E-03) [26].
rs17782313 and rs9939609 in MC4R were also studied
in patients with PCOS [18, 19]. However, understanding
obesity and overweightness, as well as PCOS, require
consideration of both gene-gene interactions and case-
control differences in BMI. Recently, the combined ef-
fect of FTO rs9939609 and MC4R rs17782313 has been
discussed in relation to obesity, breast cancer and endo-
metrial cancer [16, 27, 28]. The above-mentioned studies
revealed that an association exists between the inter-
action of FTO rs9939609 and MC4R rs17782313 and
these independent diseases, which implied a combined
effect of these two SNPs. The role of rs9939609 of FTO
and he rs17782313 of MC4R in women with PCOS is of
interest. In the present study, we chose two representa-
tive SNPs, FTO rs9939609 and MC4R rs17782313, to in-
vestigate whether there is a combined effect of the two




The study was approved by the Institutional Review Board of
the First Affiliated Hospital of Wenzhou Medical University
(IRB reference number: 2011–21, initiating and ending dates:
06/2011–06/2014). Written informed consent was obtained
from all participants.
Subjects
A total of 733 PCOS patients were recruited from the First
People’s Hospital of Huzhou from Jun 2011 to May 2014.
Diagnosis of PCOS was based on the Rotterdam Consen-
sus proposed in 2003 [29], which consists of meeting at
least two of the following criteria: oligo-/ovulation, poly-
cystic ovarian morphology, and clinical or biochemical
hyperandrogenism (hyperandrogenism, HA). The diag-
nosis of PCOS was made only when the other etiologies
for hyperandrogenemia and ovulatory dysfunction were
excluded, i.e., congenital adrenal hyperplasia, 21-hydroxylase
deficiency, androgen-secreting tumors, Cushing’s syndrome,
thyroid disease, and hyperprolactinemia. The total testoster-
one and mF-G scores were evaluated for hyperandrogenism.
A total of 892 women who were referred for routine
physical examination or tubal factor infertility wereenrolled during the same time period. All subjects in the
control group had a regular menstrual cycle (26–35 days)
and normal ovarian morphology. Additionally, their total
testosterone and mF-G score were evaluated. Written in-
formed consent was obtained from all participants.
All participants resided in Zhejiang province, were unre-
lated and at reproductive age with no hormonal therapy
for at least 3 months. The medication and weight loss his-
tories of all subjects were collected to exclude those who
were taking hypoglycemic agents or hormonal therapy.
Clinical and biochemical measurements
Height and weight were measured while participants were
dressed in underwear without shoes. BMI was calculated
as the weight in kilograms divided by the square of the
height in meters. Obesity was defined as BMI > =28 kg/m2,
and overweight was BMI > =24 kg/m2, according to Chin-
ese criteria [30]. The waist circumference was measured
midway between the lowest rib and the iliac crest. The hip
circumference was the longest measurement around the
hips. The waist-hip ratio (WHR) was defined as the waist
circumference divided by the hip circumference.
Peripheral blood samples were tested on day 2–4 of
spontaneous cycles or after cessation of bleeding from
all the subjects after a 12 h overnight fast. The follicle
stimulating hormone, luteinizing hormone, prolactin,
testosterone and estradiol levels of all subjects were
measured with a chemiluminescent analyzer (Beckman
Access Health Company, Chaska, MN, USA).
SNP genotyping
Peripheral blood samples were obtained from all partici-
pants and collected into tubes treated with the anti-
coagulant EDTA. Genomic DNA was extracted using a
QIAamp DNA mini kit (QIAGEN, Hilden, Germany) ac-
cording to the manufacturer’s protocol. Polymerase chain




56 °C) and primers of MC4R rs17782313 (forward: 5′-AG
GAAACAGCAGGGATAGGG-3′; reverse: 5′-TGCTGAG
ACAGGTTCAT AAAAAG-30, annealing temperature
56 °C). The PCR products were purified and sequenced
on an ABI 3700 automated sequencer (Applied Biosystems,
Foster City, CA, USA). Five percent of randomly selected
samples were re-sequenced to validate the genotyping assays.
Statistical analysis
Continuous parameters of patients and controls are
expressed as means ± SD. PLINK (v.1.07, http://pngu.mgh.
harvard.edu/purcell/plink) was applied to calculate the
Hardy-Weinberg equilibrium (HWE), allele frequency dif-
ferences and genotype differences. Because there were no
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(p > =0.05), genotype and allele frequencies were compared.
A power calculation was performed using a Genetic Power
Calculator [31]. Genetic models were divided into additive
(+/+ vs. +/- vs. -/-), dominant (+/+ plus +/- vs. -/-) and re-
cessive (+/+ vs. +/- plus -/-). Logistic regression for the dis-
ease trait was conducted to exclude the potential
confounding effects of age and body mass index. The geno-
type models were applied for the phenotype analysis, which
was compared by one-way ANOVA or student T test using
SPSS software (SPSS version 16, IL, USA). p < 0.05 was
considered statistically significant.Results
Clinical characteristics of subjects
Seven hundred and thirty-three PCOS patients and 892
controls were recruited, and the case-control genetic
power reached 0.8 at the p = 0.001 level. Clinical measure-
ments are presented in Table 1. In the PCOS group, 20.6 %
(150/733) of subjects were obese (BMI > =28 kg/m2), while
the percentage in the control group was only 10.1 % (90/
892). Additionally, 44.1 % (320/733) of PCOS women were
overweight or obese (BMI > =24 kg/m2), while the percent-
age in the control group was 21.9 % (196/892). There were
no differences in the waist circumference and WHR after
age and BMI were adjusted by logistic regression.Allele and genotype frequency
The observed genotype distributions of the two SNPs
were consistent with Hardy-Weinberg equilibrium. The
minor allele frequency (MAF) comparison is presented
in Table 2. The P value of rs9939609 is 0.030 (p = 0.187;
OR = 1.27; 95 % CI: 1.02–1.58), which was attenuated
after adjusting for BMI. For rs17782313, no association
with PCOS was observed (p = 0.368; OR = 1.07; 95 %
CI: 0.91–1.27), and it was also attenuated after adjusting
for BMI. The genotype comparisons are shown Table 3.
Of the three genotypes of rs9939609, the recessiveTable 1 Comparison of basic clinical characteristics between
PCOS and control subjects
Characteristics PCOS Control P P adj
AGE 26.14+/−3.23 29.38+/−4.53 <0.001 -
BMI 25.16+/−5.27 22.73+/−2.97 <0.001 -
WAIST 84.75+/−10.19 78.04+/−7.38 <0.001 0.21
WHR 0.87+/−0.06 0.84+/−0.04 <0.001 0.79
FSH 6.15+/−1.71 7.47+/−2.95 <0.001 <0.001
LH 9.82+/−5.63 4.89+/−2.29 <0.001 <0.001
T 56.61+/−22.90 21.55+/−12.51 <0.001 <0.001
SD standard error, WHR waist-hip ratio, FSH follicle-stimulating hormone, LH
luteinizing hormone, T testosterone, P adj adjusted P value by age and BMI in
logistic regressiongenotype model was the most powerful (p = 0.020). No
statistical significance was found for rs17782313.
To eliminate the influence of BMI in the association
between rs9939609, the PCOS and control subjects were
further divided into an obese/overweight group and a
non-obese/overweight group to eliminate the influence
of BMI (Table 4). The MAF of the PCOS groups was
higher (OR obese/overweight =1.31; OR non-obese/over-
weight =1.30); however, there was no significant differ-
ence between the PCOS and controls (P obese/
overweight =0.074 and P non- obese/overweight =0.247).
Moreover, there were MAF differences in the PCOS sub-
jects with different BMIs (p = 0.005, p adjusted = 0.74),
which is similar to the control group (p = 0.031, p ad-
justed = 0.21). The differences in the rs9939609 MAF be-
tween the PCOS and control groups could be explained
by the influence of the BMI.
To investigate the combined effect, we also studied the
participants who were simultaneously carrying the risk
A and C alleles of FTO or MC4R. The subjects were di-
vided into a group with both risk alleles (simultaneously
carrying the risk A and C, PCOS vs. control = 131 vs.
121), a group carrying one risk allele (carrying the risk A
or C, PCOS vs. control = 227 vs. 314), and a group with
no risk alleles. Additionally, the cluster of risk alleles has
been found in PCOS subjects (P group of risk allele =
0.017, OR = 1.38), which remained even after adjust-
ments for BMI (p = 0.031).
Clinical and metabolic measurements of different
genotypes in PCOS
According to the genetic analysis, there was an association
between rs9939609 and PCOS, but not between rs17782313
and PCOS. Furthermore, a genetic-phenotype association
study was carried out only for rs9939609. Clinical data,
particularly metabolic and lipid indices, of PCOS pa-
tients are presented in Table 5 by the additive model of
rs9939609. The BMI and waist circumference increased
along with the presence of the risk allele A. However,
the WHR was not different between the three groups.
Basic clinical indices, such as FSH, LH and T, were higher
in the AA group with no significant differences. The
fasting insulin level of OGTT was higher among pa-
tients with the AA genotype. As the homeostasis model
assessment-estimated insulin resistance (HOMA-IR)
was introduced, the increasing trend, along with the A
risk allele, was also observed.
Discussion
The mechanism underlying the association of obesity
with PCOS remains unclear. Obesity is associated with
hyperandrogenism and menstrual disturbance of PCOS
and worsening complications, such as T2DM and hyper-
tension [7, 4, 32]. However, some studies have argued
Table 2 Allele comparison of rs9939609 and rs17782313
Risk allele MAF PCOS MAF control P OR 95 % CI P adj
rs9939609 A 0.126 0.102 0.030 1.27 0.187
1.02–1.58
rs17782313 C 0.242 0.229 0.368 1.07 0.715
0.91–1.27
MAF minor allele frequency, OR odds risk, 95 % CI confidence interval, P adj, adjusted P value by BMI in logistic regression
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great extent [33] and that results may be influenced by
BMI and other adipose-related measurements. Addition-
ally, it is reasonable to study the pleotropic effects of
BMI-associated alleles in PCOS to explain the increased
BMI levels and weight in PCOS patients. The present
study was designed to investigate if the common candi-
date genes for obesity are also related to PCOS. Addition-
ally, the interaction of FTO and MC4R polymorphisms is
associated with PCOS.
In the present study, we again observed an association
between FTO and PCOS, although it was attenuated
after adjustment for BMI. In one large-scale study in a
Han Chinese population, the A allele for the FTO gene
was significantly more frequent among PCOS patients
than it was in the control population (14.1 % vs. 10.2 %;
A allele vs. T allele, OR = 1.44, P = 1.86E-09), which was
in accordance with our study [25, 22]. However, we did
not replicate the results that FTO gene is a candidate
gene for PCOS independent of BMI effects [22], poten-
tially due to our limited sample size. The other study
conducted in a Han Chinese population reported similar
results. The association between FTO and PCOS was
mediated by BMI [25]. Similar to rs9939609 of FTO, the
rs17782313 of MC4R has been reported to contribute to
elevated BMI in PCOS, but it does not appear to play a
major role in PCOS [18]. It has also been reported that
there is no association between rs17782313 and PCOS
[18]. However, when the two SNPs are considered to-
gether, a polygenetic effect is evident and the association
is seemingly more significant.Table 3 Allele and genotype analysis of rs9939609 and rs17782313
SNP Comparisons PCOS
Minor/Major
rs9939609 A/T ADD 16/153/564
DOM 169/564
REC 16/717
rs17782313 C/T ADD 35/285/413
DOM 320/413
REC 35/698
ADD additive genotype (three genotypes) study, DOM dominant genotype (homozy
REC recessive genotype study (homozygotes of risk allele vs. heterozygotes + homoThe FTO rs9939609 SNP is related to body weight
through its influence on energy intake and satiety [34].
However, the underlying association of FTO polymor-
phisms with PCOS risk remains unclear. One recent
meta-analysis suggested that the effect of the FTO poly-
morphism rs9939609 may not be associated with the risk
of PCOS in the overall population [35], and we also con-
cluded that there is a direct association between the
FTO variant and PCOS risk that is independent of BMI
(adiposity) in East Asians [25, 22]. In Asian populations,
the MAF of rs9939609 is not as high as in Caucasian
populations (43–49 %); in our study, the MAF was
12.6 % [22]. The different genetic background of differ-
ent ethnic populations may explain the discrepancy in
the MAF. Although a direct association between the
FTO variant and PCOS risk has been found [20, 22] and
successfully replicated in this study, the effect of the
FTO gene on PCOS is possibly related to its genetic
interaction with other susceptibility genes, considering
there were limited PCOS patients carrying the risk allele.
The combination of susceptibility genes may contribute to
the polygenic background of PCOS. In the present study,
we observed a significant association between FTO and
MC4R with PCOS in a Chinese population (p = 0.0014).
PCOS is considered to be complex, multifactorial or
polygenic, meaning that the disease is likely associated
with the effects of multiple genes in combination with
lifestyles and environmental factors. Traditional ap-
proaches for studying the genetic basis of PCOS have
limitations because they only target a single gene or
cluster of tightly linked genes. Genes located onControl P OR (95 % CI)
Minor/Major
7/168/717 0.030 -
175/717 0.091 1.23 (0.97–1.56)
7/885 0.020 2.82 (1.15–6.89)
27/354/511 0.187 -
381/511 0.70 1.04 (0.85–1.27)
27/865 0.067 1.61 (0.96–2.68)
gotes of risk allele + heterozygotes vs. homozygotes of non-risk allele) study,
zygotes of non-risk allele)
Table 4 rs9939609 allele comparisons of PCOS and control
divided into groups according to the presence or absence of
obesity
MAF P OR 95 % CI
PCOS Control
Obese group 0.16 0.13 0.074 1.31 (0.95–1.67)
Non-obese group 0.12 0.09 0.247 1.30 (0.92–1.68)
P adj, adjusted P value by BMI in logistic regression. The comparison of the
PCOS Obese group and Non-obese group was carried out (p= 0.005, p adj= 0.74),
which was also true for the controls (p= 0.031, p adj= 0.21)
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the genetic background of PCOS. As in the scenario in
the current study, the association of FTO with PCOS
was successfully replicated, but the association of the
MC4R polymorphism was modest. However, based on
their similar functions in control of food intake and
energy consumption, FTO may contribute to the sus-
ceptibility of PCOS in combination with MC4R, and
patients who are positive for both the FTO and the
MC4R risk alleles are more likely to suffer from PCOS
than those patients who are positive for either the FTO
or the MC4R risk alleles.Table 5 Clinical and metabolic data of rs9939609 PCOS patients
in the additive model
Genotype AA Genotype AT Genotype TT
AGE 26.82+/−4.19 26.16+/−3.65 26.40+/−3.77
BMI a, b, c 26.49+/−4.01 25.16+/−4.23 24.70+/−4.41
WAIST a, b, c 89.74+/−12.36 85.20+/−11.98 83.19+/−10.93
WHR 0.87+/−0.04 0.86+/−0.07 0.86+/−0.07
FSH 6.27+/−1.64 6.31+/−1.61 6.27+/−1.69
LH 11.35+/−5.29 10.73+/−5.89 10.54+/−6.81
T 55.92+/−25.69 53.54+/−25.18 54.82+/−24.32
GLU-0′ 5.57+/−0.73 5.33+/−0.66 5.41+/−0.82
GLU-120′ 7.73+/−1.74 6.62+/−2.01 6.65+/−2.19
INS-0′ c 15.71+/−12.11 12.55+/−9.39 12.30+/−8.24
INS-120′ 78.64+/−88.49 68.18+/−65.61 67.59+/−60.59
HOMA-IR 3.97+/−3.81 3.01+/−3.22 2.98+/−2.29
CHOL 4.53+/−0.90 4.51+/−0.92 4.55+/−0.90
TG 1.30+/−0.91 1.30+/−0.88 1.33+/−0.92
HDL 1.30+/−0.50 1.33+/−0.35 1.32+/−0.55
LDL 2.67+/−0.97 2.68+/−0.92 2.68+/−0.91
The data are presented as the mean ± SD
GLU glucose, INS insulin, HOMA-IR homeostasis model for insulin resistance,
CHOL cholesterol, TG triglycerides, HDL high density lipoprotein, LDL low
density lipoprotein
a the comparison of genotype AA vs. genotype AT is significantly
different (p < 0.05)
b the comparison of genotype AT vs. genotype TT is significantly
different (p < 0.05)
c the comparison of genotype TT vs. genotype AT is significantly
different (p < 0.05)Conclusions
A significant association was observed between PCOS
and FTO rs9939609, but the association was attenuated
after adjustment for BMI. However, MC4R rs17782313
was not related to an increased risk for PCOS, and
the interaction of FTO and MC4R polymorphisms
exhibited a more significant association with PCOS
(P = 0.031, adjusted for age and BMI), indicating a com-
bined pathogenic effect of FTO and MC4R in the devel-
opment of PCOS.
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